Analyst Peter Lawson of Barclays maintained a Buy rating on Arcus Biosciences (RCUS – Research Report), retaining the price target of $35.00.
Peter Lawson has given his Buy rating due to a combination of factors relating to Arcus Biosciences’ prospects and ongoing research, despite broader industry concerns. His confidence in the company is rooted in the distinct characteristics of their anti-TIGIT antibody, domvanalimab, and the strategic focus on gastric and lung cancers.
Lawson’s optimism is supported by the fact that Arcus’s domvanalimab has an inactive domain which may reduce adverse effects and discontinuation rates compared to competitors. Additionally, unlike Merck’s co-formulated anti-TIGIT treatment, which faced limitations in dosing flexibility and a higher discontinuation rate, Arcus maintains a more favorable position. Upcoming mature PFS data from the Phase 2 EDGE-Gastric trial and Phase 2 VELOCITY lung data, expected in 2024, also underpin Lawson’s positive outlook for Arcus Biosciences.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Arcus Biosciences (RCUS) Company Description:
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
